Changes in messenger RNA expression of protein kinase a regulatory subunit Iα in breast cancer patients treated with tamoxifen

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2399-2404

  Miller, William R ^a,b,d   Hulme, Martin J ^a   Bartlett, John M S ^c   MacCallum, Janis ^a   Dixon, J Michael ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; MESSENGER RNA; TAMOXIFEN;

AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DRUG EFFECT; DRUG EFFICACY; ENZYME INDUCTION; ENZYME LOCALIZATION; ENZYME SUBUNIT; FEMALE; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROMOLECULAR SUBSTANCES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAMOXIFEN; TRANSCRIPTION, GENETIC;

EID: 0031418311     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Tellez, C., and Jordan, V. C. Hormonal treatment of advanced breast cancer. Surg. Oncol. Clin. North Am., 4: 751-777, 1995.
2. Jackson, I. M., and Lowery, C. Clinical use of antioestrogens. In: B. J. A. Furr and A. E. Wakeling (eds.), Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action, pp. 87-105. London: Bailliere Tindall, 1987.
3. Henderson, I. C. Endocrine therapy on metastatic breast cancer. In: J. R. Harris, S. Hellman, I. C. Henderson, and D. N. Kinne (eds.), Breast Diseases, pp. 559-603. Philadelphia: J. B. Lippincott Co., 1991.
4. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet, 339: 1-15, 1992.
5. Katzenellenbogen, B. S., Miller, M. A., Mullick, A., and Sheen, Y. Y. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. Breast Cancer Res. Treat., 5: 231-243, 1985.
6. Rose, C., Thorpe, S. M., Andersen, K. W., Pedersen, B. V., Mouridsen, H. T., Blichert-Toft, M., and Rasmussen, B. B. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet, i: 16-19, 1985.
7. Rutqvist, L. E., Cedermark, B., Glas, U., Johansson, H., Nordenskjold, B., Skoog, L., Somell, A., Theve, T., Friberg, S., and Askergren, J. The Stockholm trial on adjuvant tamoxifen in early breast cancer: correlation between estrogen receptor level and treatment effect. Breast Cancer Res. Treat., 10: 255-266, 1987.
8. Stewart, H. J. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC) Edinburgh. Lancet, ii: 171-175, 1987.
9. Horobin, J. M., Preece, P. E., Dewar, J. A., Wood, R. A., and Cuschieri, A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br. J. Surg., 78: 213-217, 1991.
10. Muss, H. B. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res. Treat., 21: 15-26, 1992.
11. Wolf, D. M., and Jordan, V. C. Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Res. Treat., 27: 27-40, 1993.
12. Jordan, V. C., Fritz, N. F., Langan-Fahey, S., Thompson, M., and Tormey, D. C. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term tamoxifen monotherapy. J. Natl. Cancer Inst., 83: 1488-1491, 1991.
13. Osborne, C. K., Coronado, E., Allred, D. C., Wiebe, V., and DeGregorio, M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxy-tamoxifen. J. Natl. Cancer Inst., 83: 1477-1482, 1991.
14. Johnston, S. R. D., Haynes, B. P., Smith, I. E., Jarman, M., Sacks, N. P., Ebbs, S. R., and Dowsett, M. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet, 342: 1521-1522, 1993.
15. Keen, J. C., Miller, E. P., Bellamy, C., Dixon, J. M., and Miller, W. R. P-Glycoprotein and resistance to tamoxifen. Lancet, 343: 1047, 1994.
16. Isaacs, J. T. Clonal heterogeneity in relation to response. In: B. A. Stoll (ed.), Endocrine Management of Cancer: Biological Bases, pp. 125-140. Basel: S. Karger AG, 1988.
17. Nicholson, R. I., McClelland, R. A., Gee, J. M. W., Manning, D. L., Cannon, P., Robertson, J. F., Ellis, I. O., and Blamey, R. W. Transforming growth factor-α and endocrine sensitivity in breast cancer. Cancer Res., 54: 1684-1689, 1994.
18. Katzenellenbogen, B. S. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol. Reprod., 54: 287-293, 1996.
19. Fujimoto, N., and Katzenellenbogen, B. S. Alteration in the agonist/ antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. Mol. Endocrinol., 9: 814-825, 1994.
20. O'Malley, B. W., Schrader, W. T., Mani, S., Smith, C., Weigel, N. L., Conneely, O. M., and Clark, J. H. An alternative ligand-independent pathway for activation of steroid receptors. Recent Prog. Horm. Res., 50: 333-347, 1995.
21. Watson, D. M. A., Hawkins, R. A., Bundred, N. J., Stewart, H. J., and Miller, W. R. Tumour cyclic AMP binding proteins and endocrine responsiveness in patients with inoperable breast cancer. Br. J. Cancer, 56: 141-142, 1987.
22. Beebe, S. J., Oyen, O., Sandberg, M., Froysa, A., Hansson, V., and Jahnsen, T. Molecular cloning of a unique tissue-specific protein kinase (CY) from human testis, representing a third isoform for the catalytic subunit of the cAMP-dependent protein kinase. Mol. Endocrinol., 4: 465-475, 1990.
23. Cho-Chung, Y. S. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy. Cancer Res., 50: 7093-7100, 1990.
24. Scala, S., Budillon, A., Zhan, Z., Cho-Chung, Y. S., Jefferson, J., Tsokos, M., and Bates, S. E. Downregulation of mdr-1 expression by 8 cl-cAMP in multidrug resistant MCF-7 human breast cancer cells. J. Clin. Invest., 96: 1026-1034, 1995.
25. Bartlett, J. M. S., Hulme, M. J., and Miller, W. R. Analysis of cAMP RI α mRNA expression in breast cancer: evaluation of quantitative polymerase chain reaction for routine use. Br. J. Cancer, 73: 1538-1544, 1996.
26. Auffrey, C., and Rougeon, F. Purification of mouse immunoglobulin heavy chain messenger RNA from total myeloma tumour RNA. Eur. J. Biochem., 107: 303-314, 1980.
27. MacCallum, J., Bartlett, J. M. S., Thompson, A. M., Keen, J. C., Dixon, J. M., and Miller, W. R. Expression of transforming growth factor β mRNA isoforms in human breast cancer. Br. J. Cancer, 69: 1006-1009, 1994.
28. Keen, J. C., Dixon, J. M., Miller, E. P., Cameron, D. A., Chetty, U., Hanby, A., Bellamy, C., and Miller, W. R. The expression of Ki-S1 and Bcl-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Res. Treat., 44: 123-134, 1997.
29. Miller, W. R., Hulme, M. J., Cho-Chung, Y. S., and Elton, R. A. Types of cyclic AMP binding proteins in human breast cancers. Eur. J. Cancer, 29A: 989-991, 1993.
30. Tasken, K., Skalhegg, B. S., Solberg, R., Andersson, K. B., Taylor, S. S., Lea, T., Blomhoff, H. K., Jahnsen, T., and Hansson, V. Reciprocal regulation of messenger RNA and protein for subunits of cAMP-dependent protein-kinase (ri-α and c-α) by cAMP in a neoplastic B-cell line (reh). J. Biol. Chem., 268: 23483-23489, 1993.
31. Jackiw, V., and Hunzicker-Dunn, M. Luteinization-associated changes in protein stability of the regulatory subunit of the Type 1 cAMP-dependent protein kinase. J. Biol. Chem., 267: 14335-14344, 1992.
32. Rohlff, C., Clair, T., and Cho-Chung, Y. S. 8-Cl-cAMP induces truncation and down regulation of the RIa subunit of cAMP dependent protein kinase leading to type II holoenzyme dependent growth inhibition and differentiation of HL-60 leukemia cells. J. Biol. Chem., 268: 5774-5782, 1993.
33. Yasumoto, Y., Shimada, N., Kimura, N., and Nagata, N. Estradiol up-regulates the stimulatory GTP-binding protein expression in the MCF-7 human mammary carcinoma cell line. FEBS Lett., 322: 25-29, 1993.
34. Fissore, F., Fortunati, N., Comba, A., Fazzari, A., Gaidano, G., Berta, L., and Frairia, R. The receptor mediated action of sex steroid binding protein (SBP, SHBG): accumulation of cAMP in MCF-7 cells under SBP and estradiol treatment. Steroids, 59: 661-667, 1994.
35. Tasken, K. A., Knutsen, H. K., Attramadal, H., Tasken, K., Jahnsen, T., Hansson, V., and Eskild, W. Different mechanisms are involved in cAMP-mediated induction of mRNAs for subunits of cAMP-dependent protein kinases. Mol. Endocrinol., 5: 21-28, 1991.
36. Miyazaki, K., Miyamoto, E., Maeyama, M., and Uchida, M. Specific regulation by steroid hormones of protein kinases in the endometrium. Eur. J. Biochem., 104: 543-547, 1980.
37. Houge, G., Cho-Chung, Y. S., and Doskeland, S. O. Differential expression of cAMP-kinase subunits is correlated with growth in rat mammary carcinomas and uterus. Br. J. Cancer, 66: 1022-1029, 1992.
38. Costa, M., Gerner, E. W., and Russell, D. H. Cell cycle-specific activity of type I and type II cyclic adenosine 3′:5′-monophosphate-dependent protein kinases in Chinese hamster ovary cells. J. Biol. Chem., 251: 3313-3319, 1976.
39. Byus, C. V., Klimpel, G. R., Lucas, D. O., and Russell, D. H. Type I and type II cyclic AMP-dependent protein kinase as opposite effectors of lymphocyte mitogenesis. Nature (Lond.), 268: 63-64, 1977.
40. Cho-Chung, Y. S., Clair, T., Tortora, G, and Yokozaki, H. Role of site-selective cAMP analogs in the control and reversal of malignancy. Pharmacol. Ther., 50: 1-33, 1991.
41. Fuller, D. J. M., Byus, C. V., and Russell D. H. Specific regulation by steroid hormones of the amount of type I cyclic AMP-dependent protein kinase holoenzyme. Proc. Natl. Acad. Sci. USA, 75: 223-227, 1978.
42. Tortora, G., Clair, T., Katsaros, D., Ally, S., Colamonici, O., Neckers, L. M., Tagliaferri, P., Jahnsen, T., Robins, R. K., and Cho-Chung, Y. S. Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP dependent protein kinase. Proc. Natl. Acad. Sci. USA, 86: 2849-2852, 1989.
43. Cho, H., and Katzenellenbogen, B. S. Synergistic activation of estrogen receptor mediated transcription by estradiol and protein kinase activators. Mol. Endocrinol., 7: 441-452, 1993.
44. Bunone, G., Briand, P. A., Miksicek, R. J., and Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J., 15: 2174-2183, 1996.
45. Le Goff, P., Montano M. M., Schodin, D. J., and Katzenellenbogen, B. S. Phosphorylation of the human estrogen receptor: identification of hormone-regulated sites and examination of their influence on transcriptional activity. J. Biol. Chem., 269: 4458-4466, 1994.
46. Katzenellenbogen, B. S. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol. Reprod., 54: 287-293, 1996.
47. Abraham, I., Chin, K. V., Gottesman, M. M., Mayo, J. K., and Sampson, K. E. Transfection of a mutant regulatory subunit gene of cAMP-dependent protein kinase causes increased drug sensitivity and decreased expression of P-glycoprotein. Exp. Cell Res., 189: 133-141, 1990.
48. Rohlff, C., Safa, B., Rahman, A., Cho-Chung, Y. S., Klecker, R. W., and Glazer, R. I. Reversal of resistance to Adriamycin by 8-chloro-cyclic AMP Adriamycin-resistant HL-60 leukemia cells is associated with reduction of type I cyclic AMP dependent protein kinase and cyclic AMP response element binding protein DNA binding activities. Mol. Pharmacol., 43: 372-379, 1993.
49. Kim, S. H., Park J. I., Chung B. S., Kang C. D., and Hidaka, H. Inhibition of mdr1 gene expression by h-87, a selective inhibitor of cAMP-dependent protein-kinase. Cancer Lett., 74: 37-41, 1993.
50. Yokozaki, H., Budillon, A., Clair, T., Kelley, K., Cowan, K. H., Rohlff, C., Glazer, R. I., and Cho-Chung, Y. S. 8-Chloradenosine 3′,5′-monophosphate as a novel modulator of multidrug resistance. Int. J. Oncol., 3: 423-430, 1993.